Introduction
Angiogenesis, the formation of new blood vessels from the pre-existing vasculature, is an important component of normal physiological processes including wound healing and development (reviewed in Folkman, 1995) . Angiogenesis also contributes to several pathological situations, including tumor growth (Folkman, 1991; Yoshiji et al., 1996) , rheumatoid arthritis (Fava et al., 1994) and degenerative eye disorders (Pe'er et al., 1995; Pierce et al., 1995) . Angiogenesis is a complex process involving endothelial cell movement, proliferation, and survival, and endothelial cell-mediated degradation of the extracellular matrix. Multiple angiogenic stimulators and inhibitors regulate these processes (O'Reilly et al., 1997; Browder et al., 2000; Davis et al., 1996) .
Vascular endothelial growth factor (VEGF) is a key activator of endothelial cell functions (Keck et al., 1989; Leung et al., 1989; Ferrara and Davis-Smith, 1997) , and the utility of VEGF antagonist for blocking tumor angiogenesis and tumor growth is under clinical evaluation (Saaristo et al., 2000) . VEGF binds to two high affinity receptors, known as FLT1 and KDR, that are predominantly specific to endothelial cells (de Vries et al., 1992; Terman et al., 1992) . Both receptors contain insert sequences within their catalytic domains, seven extracellular immunoglobulin-like domains, and are closely related to the PDGF family of receptor tyrosine kinases (Shibuya et al., 1990; Terman et al., 1991; Mathews et al., 1991) . Although expression of both VEGF receptors occurs in adult endothelial cells, recent findings demonstrate that KDR, and not FLT1, is able to mediate the mitogenic, chemotactic, and survival responses to VEGF (Keyt et al., 1996; Gille et al., 2001) .
The signal transduction pathways that are initiated after VEGF binding to KDR remain incompletely understood. Six KDR tyrosine autophosphorylation sites have thus far been identified (Dougher-Vermazen et al., 1994; Takahashi et al., 2001) . Two of these, Y1054 and Y1059, are contained within the receptor's catalytic domain, and are required for allowing maximal kinase activity (Dougher and Terman, 1999; Kendall et al., 1999) . Two sites, Y951 and Y996, are contained within the kinase insert domain. KDR Y951 is a docking site for the VRAP SH2 domain containing protein, and may also bind PLCg (Wu et al., 2000a,b) . Two sites, Y1175 and Y1214, are located within the receptor's cytosolic tail . Y1175 has been implicated in two manuscripts as participating in VEGF-induced cell proliferation Dayanir et al., 2001) , although studies directed at clarifying the signaling protein that is recruited to KDR Y1175 have yielded conflicting and contradictory results. Utilizing KDR mutants introduced into primary endothelial cell lines by adenoviral vectors, it was shown that PLCg is recruited to KDR phosphotyrosine 1175 after VEGF treatment . On the other hand, another manuscript reported that the P85 subunit of PI-3 kinase, and not PLCg, bound to the same site after CSF-1 treatment of porcine aortic endothelial cells expressing a chimeric receptor consisting of the CSF-1R extracellular and the KDR intracellular domains (Dayanir et al., 2001) . A third study used the yeast two hybrid system to conclude that Sck, but not Shc, binds to the same autophosphorylation site (Warner et al., 2000) . However, our laboratory has shown that Shc is recruited to KDR Y1175 following activation by VEGF (Stoletov et al., 2001) .
A number of Src-homology 2 containing cell signaling proteins are recruited to KDR after VEGF treatment (Abedi and Zachary, 1997; Guo et al., 1995; Waltenberger et al., 1994) . Among these is Shc (Kroll and Waltenberger, 1997) , a ubiquitously expressed protein that forms complexes with the Grb2 adaptor protein, and mediates growth factor induced activation of the Ras/MAPK pathway (reviewed in Bonfini et al., 1996) . Three Shc isoforms of molecular weights 46-, 52-, and 66-kDa are expressed (Pelicci et al., 1992; Migliaccio et al., 1997) . The 46-and 52-kDa isoforms are generated through alternative initiation codons, whereas the 66-kDa isoform is an alternatively spliced variant of the 52-kDa isoform that is extended at the amino terminal end (Pelicci et al., 1992) . The different Shc isoforms suggest that Shc is most likely involved in multiple intracellular interactions extending its role beyond that of an adaptor molecule upstream of the Ras pathway.
More recently, Shc-related proteins have been identified; these are known as Sck/ShcB and N-Shc/ ShcC (O'Bryan et al., 1996; Pelicci et al., 1996; Nakamura et al., 1998) . N-Shc, like Shc, exists in more than one isoform. Shc, Sck, and N-Shc all have the same modular organization with a PTB domain, a CH1 domain, and a SH2 domain. The PTB and SH2 domains show the greatest amount of sequence homology (approximately 65%) between the three proteins. The CH1 domains of these proteins share a lower sequence homology, and each contain a Grb2 consensus-binding domain (Sonyang et al., 1994) (YVNV at Y317 in Shc, and YVNT at the same relative positions in Sck and N-Shc), suggesting that these proteins have similar interactions in vivo.
Unlike Shc that is ubiquitously expressed, Sck and N-Shc are expressed predominantly in the brain.
Northern blot hybridization demonstrates low-level expression of Sck in salivary glands, uterus, ovaries and testis (Nakamura et al., 1998) , although the cell types responsible are not known. Targeted disruption of the Shc gene is embryonic lethal due to a loss in both heart development and establishment of mature blood vessels (Lai and Pawson, 2000) . In contrast, mice in which the Sck had been disrupted develop to adulthood, but exhibit unique and overlapping losses in functions relating to neural development (Sakai et al., 2000) . Warner et al. (2000) have recently reported that Sck, but not Shc, is recruited to activated KDR when both proteins are co-expressed in human embryonic kidney epithelial cells. As Sck expression has only been definitively demonstrated in neuronal cells, the significance of this finding for endothelial cell function remain unclear. In is manuscript we extend this work by describing studies that demonstrate that Sck is expressed in vascular endothelial cells, and that the endogenously expressed protein participates in VEGFinduced signal transduction. The implication of this finding in clarifying VEGF-mediated endothelial cell activities is discussed.
Results

Sck is expressed in endothelial cells
Two experimental strategies were taken to determine whether or not Sck mRNA is present in endothelial cells. Firstly, RT -PCR was performed using primers that span the SH2 domain of Sck and mRNA prepared from three different endothelial cell lines. The primers were selected, in part, because their nucleic acid sequences have minimal homology to the Shc SH2 domain. The authenticities of the products ( Figure 1a) were confirmed by restriction digests with Sph1 which gave rise to two fragments of sizes 116 and 174 bp ( Figure 1a) ; this would be predicted from the Sck nucleic acid sequence. The PCR products were also cloned into the pBlueScript K/S plasmid, and DNA sequencing confirmed that it was Sck (data not shown). Secondly, RNase protection analysis also demonstrated that Sck mRNA is expressed in HUVE cells (Figure 1b) , confirming that Sck is expressed at the nucleic acid level in endothelial cells derived from various species.
Experiments were then done to determine whether or not expression of the Sck protein could be detected in vascular endothelial cells. For these experiments we initially set out to produce antibodies that specifically recognize the Sck protein. The Sck CH1 domain was expressed in bacteria as a GST-fusion protein, purified, and utilized as an antigen to produce both monoclonal antibodies in mice, and polyclonal antibodies in rabbits. In order to characterize the Sck protein, human astrocytes and HUVE cells were cultured on 35-mm dishes, the media aspirated, and SDS -PAGE gel sample buffer added. The cell extracts were subjected to SDS -PAGE, and Western blotting was done using the monoclonal anti-Sck antibody. As shown in Figure 2a , the antibody bound to two proteins in both cell types. One is a 68-kDa protein that corresponds to previously published data (Sakai et al., 2000; Kojima et al., 2001) . The second band is a 51-kDa protein and appears to be the predominant isoform. However, when cells were first immunoprecipitated with a polyclonal anti-Sck and then immunoblotted with the monoclonal anti-Sck, only the 51-kDa protein was detected, as shown in Figure  2b . While protease inhibitors were included at each step during the immunoprecipitation protocol, it is likely that the observed 51-kDa protein is a proteolytic fragment of the previously reported native 68-kDa Sck protein.
Figures 3 and 4 show histochemical analysis to further confirm the presence of the Sck protein in endothelial cells from different vascular beds. Sections through the heads of 3-day-old mouse pups were prepared in such a manner that we could examine the vasculature in the retina. Positive staining of endothelium can be seen using antibodies to PECAM and KDR (Figure 3a,b) . Using consecutive sections, it can be seen that these same cells stained positively for Sck (Figure 3c ). No staining of these cells was observed if preimmune serum was used as the primary antibody ( Figure 3d ). It has previously been shown that neurons express Sck, and that mice lacking Sck exhibit losses in function relating to neural development (Sakai et al., 2000) . Figure 3e shows the presence of Sck in neurons located in the olfactory bulb of the mouse pups; these cells did not show expression of KDR as shown in Figure 3f . Figure 4 shows the positive staining for Sck in endothelial cells derived from both the murine heart Figure 1 Sck mRNA is expressed in endothelial cells. mRNA was prepared from BAE, MS1, and HUVE cells. (a) RT -PCR was done using oligonucleotides that spanned the Sck SH2 domain, and the resulting PCR products are shown in lanes 1 -3. Aliquots of the PCR products were digested with the SphI restriction enzyme, and resulting products shown in lanes 4 -6. (b) RPA was done using mRNA prepared from HUVE cells. The size of the unprotected 32 P-labeled Sck RNA probe is indicated Figure 2 Sck protein is expressed in endothelial cells. (a) Human astrocytes and HUVE cells were cultured in 35 mm dishes until they were subconfluent. The cell media was aspirated, the cells washed with PBS, and gel sample buffer added directly to the well. Western blotting of the cell extracts was done using the monoclonal anti-Sck antibody. (b) HUVE cells, PAE cells and astrocytes were cultured on 10 cm dishes until they were subconfluent. The cells were washed with PBS, scraped from the dishes, and lysed with detergent. The immunoprecipitation step was done using the polyclonal anti-Sck antibody, and the immunoblotting step done using the monoclonal antibody Figure 3 Sck is expressed in the vasculature at the back of the retina in 3-day-old mouse pups. The pups were sacrificed and fixed in formalin. The entire head was sectioned so as to include the retina. Sections were deparaffinized and rehydrated, and incubated with primary antibody overnight. Positive staining was detected with DAB peroxidase substrate and counterstained with hematoxylin. Staining shown of the vasculature at the back of the retina with anti-PECAM (6100) (a), anti-KDR (6100) (b), anti-Sck (660) (c) and control with no primary antibody (660) (d). Staining shown of the neuronal cells of the olfactory bulb with anti-Sck (6100) (e), and anti-KDR (6100) (f) and also human umbilical cord. Figure 4a shows adult murine heart, endothelium is verified with anti-KDR antibody and consecutive sections also showed positive staining for Sck ( Figure 4b ). Figure 4c shows the endothelial cells lining the vein in umbilical cord sections positively stained with anti-KDR, and Figure  4d shows the same cells stained with Sck. These histological sections show that the Sck protein is expressed in various tissues from different species.
Sck participates in VEGF-induced signaling
In order to determine whether Sck plays a role in the VEGF mediated signaling cascades, HUVE cells were grown to subconfluency, serum starved and stimulated with VEGF. Cells were lysed with detergent, and both anti-Sck and anti-KDR immunoprecipitates prepared. The level of Sck tyrosine phosphorylation was analysed by Western blotting of the anti-Sck immunoprecipitates using an anti-pTyr antibody. The recruitment of Sck to KDR was analysed by Western blotting of the anti-KDR immunoprecipitates using the anti-Sck antibody. VEGF treatment led to a twofold increase in level of Sck tyrosine phosphorylation ( Figure 5a ) and a twofold increase in the recruitment of Sck to KDR (Figure 5b ). Taken together, these results demonstrate that VEGF treatment of HUVE cells leads to both the recruitment of Sck to KDR, as well as Sck tyrosine phosphorylation.
We had previously reported (Stoletov et al., 2001 ) that Shc is recruited to phosphotyrosine 1175 of activated KDR (KDR Y1175), and tested whether this is also the case for Sck. For this experiment, PAE cells were transfected with both native KDR and KDR mutated at tyrosine 1175 (KDR(Y1175F)), and receptor expressing cell lines were selected using antibiotics and expanded. Figure 6a demonstrates that receptor autophosphorylation was easily detected after VEGF treatment of KDR(Y1175F) expressing cells.
When we examined VEGF-induced recruitment of Sck to KDR, we detected a 2.2-fold increase for cells expressing native receptor, but no increase for cells expressing KDR(Y1175F) (Figure 6b ). Figure 6c shows the same blot stripped and re-probed for NCK, a signaling protein known to be activated following VEGF stimulation of KDR. Here we see an increase in VEGF-induced recruitment of NCK to KDR in both cells expressing native receptor (twofold) and cells expressing KDR(Y1175F) (2.8-fold). It is concluded from this result that, as is the case for Shc, Sck is recruited to KDR Y1175 after VEGF treatment.
The interaction of Shc with many activated receptor tyrosine kinases is mediated through the Shc PTB domain (Kavanaugh and Williams, 1994) . Neither KDR Y1175, nor any other receptor tyrosine residue, is contained within a PTB consensus binding amino acid sequence. KDR Y1175 is contained within a Shc SH2 domain consensus binding amino acid sequence (Sonyang et al., 1993) , and experiments were then done to determine whether Shc and Sck bind via their SH2 domain to activated KDR. The strategy taken was to test whether recombinant Shc and Sck SH2 domains bind to a tyrosine phosphorylated synthetic peptide Figure 4 Sck is expressed in the vasculature of the adult mouse heart and the endothelium lining the unbilical vein in human umbilical cords. Adult mice were sacrificed and the hearts fixed in formalin. Sections were incubated with primary antibody (anti-KDR (660) (b), and anti-Sck (6100) (b)). Fresh umbilical cords were fixed in formalin and cross-sections cut to bisect the vein. Staining shown with anti-KDR (660) (c) and anti-Sck (660) (d) Figure 5 VEGF stimulates Sck tyrosine phosphorylation and the recruitment of Sck to KDR. HUVE cells were grown on 10 cm dishes until they were subconfluent, treated with or without VEGF, and solubilized with detergent. Immunoprecipitates were prepared using either anti-Sck (a) or anti-KDR (b). The samples were subjected to SDS -PAGE, and Western blotting was done using either anti-pTyr (a) or anti-Sck (b). The blot shown in (b) was stripped and reprobed using anti- KDR (c) derived from the amino acid sequence adjacent to KDR Y1175. The peptide was synthesized using biotin, and then coupled to sepharose. The recombinant SH2 domains were expressed as GSTfusion proteins, this was taken advantage of for protein detection. Figure  7a shows that the recombinant Shc SH2 domain binds to the tyrosine phosphorylated KDR Y1175 peptide, but not to the peptide if it was synthesized using tyrosine and not phosphotyrosine. The Shc SH2 domain does not bind to tyrosine phosphorylated peptides derived from other potential KDR autophosphorylation sites. Figure 7b shows that a recombinant Sck SH2 domain protein also interacts with the tyrosine phosphorylated KDR Y1175 peptide. For this experiment, the Shc and Sck SH2 domains bound to nonphosphorylated KDR Y1175 peptide, but not nearly to the degree that bound to tyrosine phosphorylated peptide.
It has been previously reported that VEGF treatment leads to the recruitment of PLCg to KDR Y1175. Our findings that the Shc and Sck SH2 domains bind directly to KDR Y1175 prompted experiments directed at determining whether PLCg also binds directly to KDR Y1175, or is recruited to the receptor by interacting with Shc, Sck or another intermediate. Figure 7c demonstrates that a recombinant GST-fusion protein containing both PLCg SH2 domains binds to tyrosine phosphorylated peptides derived from both KDR Y1175, and the bPDGF Y1021, a known PLCg binding site (Songyang et al., 1993) . In contrast to the results seen using the recombinant PLCg SH2 domain, the recombinant Sck SH2 domain interacts with the tyrosine phosphorylated KDR Y1175 peptide, but not the bPDGFR derived peptide.
The results of Figure 7 indicate that PLCg, Sck, and Shc are each recruited to the KDR pY1175. This finding implies that the VEGF-induced signaling might be dictated by the ability of PLCg, Sck, and Shc to compete with each other for binding to the autophosphorylation site. To test this hypothesis, an experiment was performed to test whether a dominant-negative Shc or Sck protein would block PLCgmediated signaling activity. Figure 7 The Sck SH2 domain binds directly to KDR Y1175. (a) Biotinylated KDR-derived synthetic peptides derived from several potential autophosphorylation sites were synthesized using either phosphotyrosine or tyrosine, and coupled to avidin agarose. The resins were incubated with the recombinant Sck SH2 domain GST-fusion protein, washed, and boiled in SDS -PAGE gel sample buffer. Western blotting was done using anti-GST. (b) Biotinylated KDR Y1175 peptide was synthesized with or without phosphotyrosine. Recombinant Sck (lanes 1 -3) or Shc (lanes 4 -6) were incubated with agarose-coupled phosphorylated peptide (lanes 1 and 4), agarose-coupled non-phosphorylated peptide (lanes 2 and 5), or avidin agarose (lanes 3 and 6). Western blotting was done using anti-GST antibodies. (c) Recombinant PLCg (lanes 4 -6) or Sck (lanes 1 -3) SH2 domains were incubated with agarose-coupled tyrosine phosphorylated bPDGFR derived peptide (lanes 1 and 4), avidin agarose-coupled tyrosine phosphorylated KDR Y1175 peptide (lanes 2 and 5) and avidin agarose (lanes 3 and 6). Western blotting was done using anti-GST antibodies
The dominant-negative Shc and Sck proteins used for these experiments were the bacterially expressed SH2 domains. These proteins were expressed as chimeras containing at their carboxy-terminal ends a 16 amino acid cellular internalization sequence derived from the homeodomain of antennapedia (AP), a Drosophilae transcription factor. The AP protein facilitates the homogeneous uptake of peptides or oligonucleotides into cultured mammalian cells through a non-endocytic nondegenerative pathway (Derossi et al., 1996 (Derossi et al., , 1998 Bucci et al., 2000) .
It was previously documented that PLCg recruitment to KDR pY1175 mediates VEGF-induced P44/42 MAPK activity. This conclusion was confirmed by the results of an experiment taking a complementary strategy to that previously reported; that is, a pharmacological inhibitor (U73122 (Calbiochem)) of PLCg enzymatic activity was shown to inhibit VEGFinduced MAPK phosphorylation (Figure 8a ). This experiment was done using Bovine Pulmonary Artery Endothelial (BPAE) cells, although identical results were observed using KDR-transfected PAE cells (data not shown). Prior incubation of BPAE cells with either recombinant Sck or Shc SH2 domain/AP fusion proteins (Sck-AP and Shc-AP) attenuated VEGFinduced MAPK phosphorylation (Figure 8a,b) . The inhibitory effects of Sck-AP and Shc-AP were dependent on both dose and time of incubation prior to VEGF addition (data not shown). However, incubation of cells with recombinant Sck or Shc proteins not containing the AP-derived amino acids, or incubation with a recombinant AP-fusion protein derived from Nck, another signaling protein, had no effect on MAPK activation (Figure 8b ).
To rule out the possibility that the effects of Sck-AT and Shc-AT are due to nonspecific cellular effects, we tested for the effect of these proteins on VEGF-induced focal adhesion formation, a cellular response that is independent of these signaling proteins. The effect of Nck-AT was also tested for, as we had previously reported that Nck plays a necessary role in this cellular process (Stoletov et al., 2001) . Figure 9 shows the results of immunofluorescent staining of control and VEGF-treated HUVE cells using an antibody to focal adhesion kinase (FAK). FAK showed a diffuse cellular distribution in control cells, and VEGF stimulated a redistribution of FAK to focal adhesions. The assembly of focal adhesions was blocked by Nck-AT, and Sck-AT had no effect.
Discussion
Sck was originally identified by low-stringency hybridization of brain cDNA libraries using a Shc probe (O'Bryan et al., 1996; Pelicci et al., 1996; Nakamura et al., 1998) . Northern blot analysis demonstrated that Sck is expressed in certain tissues other than brain, although the cell types involved were not identified Nakamura et al., 1998 ). Our results demonstrate that Sck is expressed in vascular endothelial cells derived from a variety of tissues, but not in the other cells that comprise mature blood vessels.
With one exception, none of the previous reports examining aspects of Sck biology studied the endogenously expressed protein; instead, mRNA expression was monitored using hybridization protocols Nakamura et al., 1998) , or recombinant protein was studied (Kojima et al., 2001) . The one study examining endogenously expressed Sck protein was that of Sakai et al. (2000) who utilized antibodies to confirm loss of protein in Sck knockout mice. Our study confirms that Sck protein can be readily detected in cell extracts using specific antibodies, and we showed that endogenously expressed Sck interacts with receptor tyrosine kinases after growth factor treatment.
The structural similarities between Shc and Sck imply that the functions played by the two signaling proteins in VEGF-induced activities are interrelated. Our results demonstrating that both Shc and Sck bind VEGF-activated KDR at the same phosphotyrosine strengthens this hypothesis. Shc and Sck contain features that are both similar and different from each other, and so it may be speculated that they function in both overlapping and distinct manners. One possible working hypothesis would be that the non-conserved Figure 8 Sck-AT and Shc-AT block VEGF-induced MAPK activation. (a) BPAE cells were grown until confluent on 24-well dishes, and incubated 4 h in serum free media. The PLCg inhibitor U73122 was added at the concentrations indicated for 15 min at 378C and then VEGF was added as indicated for 5 min. Western blotting was done using an antibody to phosphorylated MAPK. (b and c) the recombinant Sck-AT, Shc-AT, Sck, and Nck-AT proteins were added in the amounts indicated 2 h prior to VEGF treatment. The upper results in (b and c) were blotted using anti-phosphorylated MAPK and the lower results were blotted using anti-MAPK CH1 domains of these proteins allow Sck and Shc to mediate distinct signal transcuction pathways. Other models predicting Sck's role in VEGF actions are plausible, including the hypothesis that Sck acts only to inhibit Shc activities, or alternatively, that the functional roles of the two proteins are redundant.
Our finding that both Sck and Shc interact with activated KDR through their SH2 domains is somewhat unusual compared to that observed for other receptor tyrosine kinases, including the EGFR , TrkA (Dikic et al., 1995) , Insulin Receptor (He et al., 1995) , and Flt4/VEGFR3 (Fournier et al., 1996) , that primarily bind the Shc PTB domain. KDR is not unique in this regard as the bPDGFR also binds the Shc SH2 domain. While we did not test whether the Sck or Shc PTB domains interact with KDR, it is unlikely that this would be the case since KDR does not contain a NXXY consensus PTB binding sequence (Kavanaugh and Williams, 1994) . Future studies will be needed to determine the endothelial cell proteins that interact with the Sck and Shc PTB domains. The Shc PTB domain is known to bind acidic phospholipids (Ravichandran et al., 1997) , which may assist in the recruitment of Shc proteins to membranes, and this may prove to be the case in VEGF-treated endothelial cells.
It has recently been reported that KDR Y1175 is a major autophosphorylation site, that when phosphorylated physically associates with the PLCg C-terminal SH2 domain . Our results indicating that the SH2 domains of both Shc and PLCg bind at Y1175 site is consistent with what is known concerning the recognition motifs for these two proteins (Songyang et al., 1993 (Songyang et al., , 1994 . That is, KDR phosphotyrosine 1175 plus the three immediate C-terminal amino acids (pYIVL) serve as an ideal recognition motif for both the Shc SH2 domain and the PLCg C-terminal SH2 domain. Sck most likely does not recognize the known aPDGFR derived PLCg-recognition motif pYIIP (Figure 7) because Sck, unlike PLCg, cannot interact with a proline at position phosphotyrosine +3.
Both PLCg and Shc are recruited to a number of the same RTKs (e.g. EGFR, TrkB, aPDGFR) after growth factor stimulation, and in each case they bind to distinct phosphotyrosines on those RTKs. This would have been predicted based upon the fact that it is the Shc PTB domain that typically recognizes activated receptor tyrosine kinases, and that the recognition amino acid motif for binding the PTB domain is quite different than the motif required for binding the PLCg SH2 domains. Our findings are the first example of a growth factor receptor tyrosine kinase that recruits both PLCg and members of the Shc family of signaling proteins to the same autophosphorylation site. This is significant, in part, because it implies that cellular responses to VEGF may be dependent upon the ability of Sck, Shc, and PLCg to compete with each other for binding to activated KDR. This hypothesis implies that changes in the expression of these signaling proteins may alter VEGFinduced cellular responses.
Sck is recruited to KDR after VEGF treatment implying that Sck participates in the angiogenic response, although the specific role it plays is not clear. For many growth factor receptors, Shc acts to recruit Grb2 to the cell surface and allow for MAPK activation. This does not appear to be the case for VEGF because we (data not shown), and others (Takahashi et al., 1999) , have not been able to demonstrate the recruitment of Grb2 to KDR or Shc after growth factor treatment. Sck-deficient mice develop to adulthood without any apparent alterations in their cardiovascular systems, a finding that is quite different from that made for Shc, which plays a necessary role in both heart development and establishment of mature blood vessels. While Sck most likely does not participate in vasculogenesis during embryo development, it is quite possible that Sck contributes to the angiogenic response in adults during wound healing or in pathological circumstances such as tumor growth. Such a role for Sck would be similar to that observed for other proteins, such as Src (Eliceiri et al., 1999) and PlGF (Carmeliet et al., 2001) where normal angiogenesis is observed in mice lacking these proteins, but altered neovascularization is displayed in certain pathological situations.
Materials and methods
Cell culture
Human umbilical vein endothelial (HUVE) cells were harvested from fresh umbilical cords as previously described (Jaffe et al., 1973) . Bovine Pulmonary Artery Endothelial (BPAE) cells were purchased from VecTechnologies and Figure 9 NckAT, but not SckAT, inhibits the VEGF-induced assembly of focal adhesions in HUVE cells. HUVE cells were plated on 8-well Permanox plastic chamber slides coated with 0.2% gelatin and grown until they were subconfluent. The cells were serum starved, and 20 mg of Sck-AT (c) or Nck-AT (d) were added. Cells were either untreated (a) or incubated with VEGF (b -d) for 20 min. Cells were fixed, permeabilized, and incubated with antibody to FAK. Immunofluorescent straining was performed as described under Materials and methods. The results shown are representative of at least 10 different fields observed in each experiment, and three similar independent experiments passage 3 -10 cells were used. Cells were cultured on 0.2% gelatin coated plates in M199 containing 10% fetal calf serum, 100 units/ml penicillin, 100 mg/ml streptomycin and 150 mg/ml endothelial cell growth supplement. Porcine aortic endothelial (PAE) cells, bovine aortic endothelial (BAE) cells, and murine pancreatic endothelial (MS1) cells (Arbiser et al., 1997) were maintained in culture in DMEM containing 10% fetal calf serum plus antibiotics.
Antibodies
The polyclonal anti-KDR antibody was isolated in our laboratory and targets the bacterially expressed KDR cytosolic domain (Dougher-Vermazen et al., 1994) . This antibody was used for immunoprecipitation and Western blotting. A polyclonal anti-KDR antibody was also purchased from Santa Cruz Biotechnology (sc-505), and used for immunohistochemistry. The polyclonal and monoclonal anti-Sck antibodies were developed in our laboratory and target the bacterially expressed human Sck CH1 domain. Anti-phosphotyrosine (PY20) was from Transduction Laboratories. The anti-MAPK antibodies were from Cell Signaling. Peroxidase-conjugated anti-GST antibodies, and donkey anti-rabbit and sheep anti-mouse immunoglobulins were from Amersham Pharmacia Biotech. Anti-PECAM used for histochemistry was from PharMingen International.
PCR of Sck SH2 Domain cDNA mRNA was isolated from cultured cells using Qiagen Oligotex Direct mRNA mini kit according to the provided protocol. Reverse transcription was carried out using a Stratagene First Strand Kit. PCR was performed using 2 ml cDNA for 40 cycles, each cycle was 30 s at 948C, 1 min at 548C, and 1 min at 728C. The oligonucleotide primers were: 5'-TGG TAC CAC GGC CGG ATG AGC and 5'-GGG CTC CCG TCA GAC CAC GCC.
RNase protection assay (RPA)
A Sck-derived cDNA clone (IMAGE: 2373589) was purchased from Incyte Pharmaceuticals, and utilized together with the PCR reaction to isolate a 170-bp product corresponding to a portion of the Sck SH2 domain. The oligonucleotide primers used for PCR were: 5'-AAA GTC GAC TGG TAC CAC GGC CGG ATG and 5'-AAA GAA TTC GGG CTC CCG TGA GAC CAC GC. Each oligonucleotide contained a restriction site (underlined) 5' to the Sck sequence. The PCR product was subcloned in pBluescript II KS plasmid (Stratagene) in antisense orientation. After linearization, the plasmid was ready to use as a template to generate a RPA probe. RPA was performed using the Pharmingen RiboQuant Multi-Probe RNase Protection Assay System (as described by the manufacturer). Briefly, 10 mg of total HUVE cell RNA was hybridized with a 32 P-UTP-labeled RNA probe overnight at 568C in hybridization buffer. RNase A and RNase T1 were added, and the sample incubated for 45 min at 308C. A Proteinase K cocktail was added, and the sample incubated for 15 min at 378C. Following phenol extraction and ethanol precipitation, the protected fragments were resolved on a 5% denaturing polyacrylamide gel and visualized using autoradiography.
Western blotting
HUVE and transfected PAE cells were grown on 10-cm dishes until subconfluent. The cells were incubated in serumfree DMEM containing 1 mM Na 3 VO 4 for 1 h at 48C. VEGF (50 ng/ml) was then added for 4 h at 48C. Cells were lysed in lysis buffer (10 mM Tris-HCl, pH 8.0, 50 mM NaCl, 0.2 mM Na 3 VO 4 , 30 mM Na 4 P 2 O 7 , 30 mM NaF, 1 mM EDTA, 1 mg/ ml leupeptin, 0.7 mg/ml pepstatin A and 1% Triton-X-100), 1 ml lysis buffer per dish. Primary antibodies were incubated with the lysates overnight at 48C. Protein A agarose (Sigma), 20 ml, was added, and the samples incubated 1 h at 48C. The resin was washed five times with lysis buffer, and then boiled in 40 ml of SDS -PAGE sample buffer. Proteins were separated by SDS -PAGE, and transferred to nitrocellulose (Biorad). The filters were blocked in Tris-buffered saline containing 0.2% Tween plus 5% dry milk or 1% BSA at 48C overnight, and then probed with specific secondary antibodies for 2 h at room temperature. After washing, the filters were incubated with horse-radish peroxidase-linked anti-rabbit or antimouse IgG, and reactions visualized through chemiluminescence (ECL; Amersham Pharmacia Biotech).
Site-directed mutagenesis of KDR cDNA
For substitution of KDR tyrosine residue 1175 with phenylalanine, site directed mutagenesis was carried out using an Amersham Pharmacia Biotech USE mutagenesis kit. The following oligonucleotide was used: 5'-GAA GAA CAA TGA AGT CTT TGC CA-3'. Mutagenesis was confirmed by DNA sequencing. The resulting vector was transfected into PAE cells, and stable transfectants were selected and expanded as previously described (Tao et al., 2001) .
Histochemistry
Formalin fixed paraffin embedded tissue sections of adult murine heart, human umbilical cord and complete coronal sections of murine skull were deparaffinized and rehydrated. Endogenous peroxidase activity was quenched with hydrogen peroxide and the sections were blocked with 1.5% serum. Anti-KDR, anti-PECAM and anti-Sck primary antibodies were incubated overnight at 48C. Biotin conjugated secondary antibodies were incubated for 30 min at room temperature followed by a 30 min incubation with avidinbiotin enzyme reagent. DAB peroxidase substrate was incubated for 2 min and sections were counterstained with hematoxylin. Sections were dehydrated and mounted with permount.
Interaction of recombinant SH2 domains with KDR-derived peptides
Sck (IMAGE:2373589) and Shc (IMAGE:309796) derived cDNAs were purchased from Incyte Pharmaceuticals. cDNA corresponding to the SH2 domains of these proteins were amplified using PCR, and DNA sequencing confirmed the identity of the PCR products. cDNA encoding both SH2 domains of PLCg was isolated from a human brain cDNA library (Clonetech) using PCR and oligonucleotides which span this region. A BamHI restrictions site was incorporated into each of the primers so as to facilitate cloning of the PCR products into the pGEX4.1 plasmid (Amersham Pharmacia Biotech.). A 200 ml culture of E. coli was grown in ampicillin at 378C to an optical density of 0.5. IPTG, 1 mM, was added and the cultures were grown at room temperature for 4 h. The cultures were centrifuged, and the cell pellets suspended in 25 ml of 10 mM Tris, pH 8.0, 1% NP40. The samples were subjected to three cycles of freeze/thaw. DNase, 50 U/ml, was added and the samples were incubated at room temperature for 20 min. The samples were centrifuged at 12 000 r.p.m. for 15 min. The recombinant SH2 domains were purified using glutathione-affinity resins as recommended by the manufacturer.
Biotinylated peptides encompassing KDR Y1175 (b-GKDYIVLPI), KDR Y1030 (b-APDYTTPEM), KDR Y996 (b-APEDLYKDFLTL), KDR Y951 (b-QGKDYV-GAIP) and bPDGFR Y1021 (b-DNDYIIPLP) were synthesized with or without using phosphotyrosine. The peptides, 5 mg, were incubated with 25 ml of streptavidincoupled agarose in 1 ml of TBS-T containing 5% BSA for 2 h at 48C. The resin was washed five times with this buffer and suspended in 1 ml. The recombinant SH2 domains, 10 mg, were added and the resin rocked for 1 h at room temperature. The resin was washed five times with TBS-T and then boiled in 40 ml of SDS -PAGE gel sample buffer. Samples were run on 12% polyacrylamide gels, followed by Western analysis using an antibody to glutathione Stransferase.
Expression of recombinant Shc and Sck SH2 domainantennapedia peptide proteins PCR was performed in order to extend the Sck and Shc SH2 domain cDNAs with DNA encoding the antennapedia peptide RQIKIWFQNRRMKWKK. Two rounds of PCR were performed in order to achieve this. For Sck, the antisense oligonucleotide utilized during the first round was 5'-GTT CTG GAA CCA GAT CTT GAT CTG TCT GGG CTC CCG TGA CAC CAC; the DNA derived from the Sck SH2 domain is underlined, and the rest of the sequence is derived from the amino-terminal portion of the antennapedia peptide. For Shc, this oligonucleotide was 5'-GTT CTG GAA CCA GTA CTT GAT CTG TCT CAG TTT CCG CTC CAC AGG. The antisense oligonucleotide utilized during the second round for both Sck and Shc was 5'-AAA GGA TCC TCA CTT CTT CCA CTT CAT CCT CCT GTT CTG GAA CCA GAT CTT, this sequence was derived from the carboxy-terminal portion of the antennapedia peptide. This oligonucleotide contains a BamHI restriction site (underlined) that was used for cloning into the pGEX4.1 expression vector, and a stop codon (in italics). The resulting plasmid was transformed into BL21 E. coli. DNA sequencing confirmed the correctness of the inserts.
The recombinant protein was expressed and purified as described above. The purified protein was dialyzed against phosphate-buffered saline for 4 h and then treated with thrombin, 5 U/ml, at room temperature for 16 h. The thrombin was removed by incubating the samples with 20 ml benzamidine sepharose at room temperature for 20 min, and then removing the resin by centrifugation. Protein was determined using the Bradford reagent (Biorad).
VEGF-induced p44/42 MAPK activation BPAE cells were cultured until subconfluent on 24-well dishes. The cells were incubated in 0.5 ml serum free media at 378C for 4 h prior to VEGF treatment. VEGF, 50 ng/ml, was added directly to the cells. After a 5-min incubation, the media was aspirated, and 150 ml of gel sample buffer added. The cell extracts were transferred to eppindorf tubes and boiled for 5 min. Thirty ml were loaded onto 12% SDS -PAGE gels. Western blotting was done using a polyclonal antibody to phospho-p44/p42.
Immunostaining assay
HUVE cells were plated on eight-well Permanox plastic chamber slides coated with 0.2% gelatin, grown until 50% confluent, and incubated in serum free media for 4 h. Sck-AT or Nck-AT, 20 mg, were added for 2 h and VEGF, 50 ng/ml, was added for 20 min. Cells were fixed in 3.5% formaldehyde in PBS for 10 min at room temperature, and non-specific binding was blocked with Hanks' solution containing 1% BSA and 10% goat serum for 1 h at room temperature. FAK (1 mg/ml) antibodies were added and incubated for 1 h at room temperature. The slides were washed three times with Hanks' solution containing 1% BSA, followed by a 1 h incubation with secondary Cy-3 conjugated goat anti-mouse antibodies (Jackson Laboratories). After washing three times with Hanks' solution containing 1% BSA, cells were viewed under a Nikon fluorescent microscope.
